Effectiveness of sitagliptin in Cystic Fibrosis with impaired glucose tolerance

Brief Description Of Study

Patients with Cystic Fibrosis often suffer from glucose intolerance. This study will evaluate how effective sitagliptin, a DPP-IV inhibitor, is at improving glycemic control in the Cystic Fibrosis population. Participants will complete baseline testing, then will be asked to take a once-daily pill for 6-months before completing follow-up testing. Participants are compensated $650 for completing study procedures.

Clinical Study Identifier: 818014

Detailed Study Description

This trial will evaluate the participant's metabolic response pre- and post-treatment using a Mixed Meal Tolerance Test and a Glucose Potentiated Arginine Test. After successful Screening, patients will undergo metabolic testing on two separate days before starting study drug or placebo. After 6-months, participants will return for two days of follow-up testing. Participants are compensated $650 for time and inconvenience of Study Visits.

Additional Information About The Study

Please contact the Research Coordinator for with further questions or to schedule a Screening Visit: Jack Eiel jack.eiel@uphs.upenn.edu 215-746-2081

Contact research investigator to learn more about this study by filling out the form below.

To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: Effectiveness of sitagliptin in Cystic Fibrosis with impaired glucose tolerance
Included below is some of my health information:
  1. Condition = Cystic fibrosis
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.